Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A03532 | 33966599 | Autophagy | Lipotoxicity reduces DDX58/Rig-1 expression and activity leading to impaired autophagy and cell death. | 2021 | Details |
| A03536 | 33965477 | J Hepatol | Surveillance of patients with cirrhosis remains suboptimal in the United States. | 2021 | Details |
| A03543 | 33962045 | Ann Hepatol | Assessment of hepatic fatty acids during non-alcoholic steatohepatitis progression using magnetic resonance spectroscopy. | 2021 | Details |
| A03545 | 33961787 | Lancet Gastroenterol Hepatol | Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. | 2021 | Details |
| A03549 | 33961302 | Hepatology | The Emerging Role of B Cells in the Pathogenesis of NAFLD. | 2021 | Details |
| A03558 | 33955510 | Mol Med Rep | Parthenolide plays a protective role in the liver of mice with metabolic dysfunction‑associated fatty liver disease through the activation of the HIPPO pathway. | 2021 | Details |
| A03563 | 33953582 | Diabetes Metab Syndr Obes | Correlation Between 25-Hydroxyvitamin D Level and Cardiac Diastolic Dysfunction in Chinese Adults with Early-Onset Type 2 Diabetes Mellitus: A Cross-Sectional Study. | 2021 | Details |
| A03564 | 33952843 | Nihon Yakurigaku Zasshi | [The roles of gap junctional intercellular communication in non-alcoholic steatohepatitis (NASH) and liver fibrosis]. | 2021 | Details |
| A03569 | 33951121 | J Gastrointestin Liver Dis | Association between Sarcopenic Obesity and Nonalcoholic Fatty Liver Disease and Fibrosis detected by Fibroscan. | 2021 | Details |
| A03571 | 33950921 | Medicine (Baltimore) | Serum markers for predicting advanced fibrosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease. | 2021 | Details |
| A03572 | 33948987 | FASEB J | Porphyran-derived oligosaccharides alleviate NAFLD and related cecal microbiota dysbiosis in mice. | 2021 | Details |
| A03580 | 33946377 | Medicina (Kaunas) | The Impact of Increased Fib-4 Score in Patients with Type II Diabetes Mellitus on Covid-19 Disease Prognosis. | 2021 | Details |
| A03583 | 33943028 | J Diabetes Investig | Liver fibrosis is independently associated with diabetic peripheral neuropathy in type 2 diabetes mellitus. | 2021 | Details |
| A03585 | 33941551 | BMJ Open Diabetes Res Care | Insulin resistance and liver histopathology in metabolically unhealthy subjects do not correlate with the hepatic abundance of NLRP3 inflammasome nor circulating IL-1β levels. | 2021 | Details |
| A03587 | 33941179 | Biomed Eng Online | Viscoelasticity measured by shear wave elastography in a rat model of nonalcoholic fatty liver disease: comparison with dynamic mechanical analysis. | 2021 | Details |
| A03592 | 33939147 | Dig Dis Sci | Impact of a Pilot Structured Mobile Technology Based Lifestyle Intervention for Patients with Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A03593 | 33939118 | Drugs | Targeting AMPK by Statins: A Potential Therapeutic Approach. | 2021 | Details |
| A03594 | 33938630 | Liver Int | Effects of intragastric balloon in patients with nonalcoholic fatty liver disease and advanced fibrosis. | 2021 | Details |
| A03599 | 33937277 | Front Med (Lausanne) | Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. | 2021 | Details |
| A03600 | 33937257 | Front Cell Dev Biol | Autophagy in Hepatic Steatosis: A Structured Review. | 2021 | Details |
| A03602 | 33935810 | Front Physiol | Serum Creatinine-to-Cystatin C Ratio in the Progression Monitoring of Non-alcoholic Fatty Liver Disease. | 2021 | Details |
| A03609 | 33932956 | J Physiol | NAD+ and NAFLD - caution, causality and careful optimism. | 2021 | Details |
| A03610 | 33932796 | Clin Nutr | Beverages and Non-alcoholic fatty liver disease (NAFLD): Think before you drink. | 2021 | Details |
| A03615 | 33930586 | Clin Res Hepatol Gastroenterol | Pathogenetic mechanisms of nonalcoholic fatty liver disease and inhibition of the inflammasome as a new therapeutic target. | 2021 | Details |
| A03618 | 33928675 | Hepatology | Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes. | 2021 | Details |
| A03619 | 33928671 | Hepatology | Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art. | 2021 | Details |
| A03624 | 33926073 | Diagnostics (Basel) | Quantification of Liver Fibrosis, Steatosis, and Viscosity Using Multiparametric Ultrasound in Patients with Non-Alcoholic Liver Disease: A "Real-Life" Cohort Study. | 2021 | Details |
| A03627 | 33925569 | Diagnostics (Basel) | Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for the Diagnosis of Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A03629 | 33924909 | Diagnostics (Basel) | Liver Fibrosis and Steatosis in Alström Syndrome: A Genetic Model for Metabolic Syndrome. | 2021 | Details |
| A03631 | 33924165 | Int J Mol Sci | Flame Retardants-Mediated Interferon Signaling in the Pathogenesis of Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A03633 | 33923817 | Int J Mol Sci | Role of Insulin Resistance in MAFLD. | 2021 | Details |
| A03635 | 33923525 | Nutrients | The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights. | 2021 | Details |
| A03637 | 33923295 | Int J Mol Sci | Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk. | 2021 | Details |
| A03638 | 33923255 | Nutrients | Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. | 2021 | Details |
| A03642 | 33922256 | Molecules | Exploratory Study Using Urinary Volatile Organic Compounds for the Detection of Hepatocellular Carcinoma. | 2021 | Details |
| A03650 | 33920670 | Int J Mol Sci | Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC. | 2021 | Details |
| A03654 | 33918467 | Biomedicines | Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review. | 2021 | Details |
| A03657 | 33917919 | Cancers (Basel) | The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients. | 2021 | Details |
| A03676 | 33908180 | J Hepatobiliary Pancreat Sci | Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy-confirmed NAFLD. | 2021 | Details |
| A03683 | 33903148 | Gut | Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug target. | 2021 | Details |
| A03687 | 33902187 | Zhonghua Gan Zang Bing Za Zhi | [Metabolic-associated fatty liver disease-related liver cirrhosis and cryptogenic liver cirrhosis]. | 2021 | Details |
| A03692 | 33901295 | Hepatology | Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH. | 2021 | Details |
| A03697 | 33899443 | Sheng Wu Yi Xue Gong Cheng Xue Za Zhi | [A review on cell-based models of human liver disease in vitro]. | 2021 | Details |
| A03698 | 33899143 | Eur Radiol | Magnetic resonance elastography biomarkers for detection of histologic alterations in nonalcoholic fatty liver disease in the absence of fibrosis. | 2021 | Details |
| A03701 | 33898959 | JHEP Rep | Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases. | 2021 | Details |
| A03702 | 33898958 | JHEP Rep | Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD. | 2021 | Details |
| A03703 | 33897617 | Front Endocrinol (Lausanne) | Mining Gut Microbiota From Bariatric Surgery for MAFLD. | 2021 | Details |
| A03704 | 33897616 | Front Endocrinol (Lausanne) | Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis. | 2021 | Details |
| A03707 | 33896117 | Liver Int | Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease. | 2021 | Details |
| A03708 | 33896100 | Liver Int | Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. | 2021 | Details |
| A03710 | 33895552 | Biochem Biophys Res Commun | The PDE5 inhibitor udenafil ameliorates nonalcoholic fatty liver disease by improving mitochondrial function. | 2021 | Details |
| A03712 | 33895182 | Metabolism | The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis. | 2021 | Details |
| A03714 | 33894425 | Cell Mol Gastroenterol Hepatol | Caspase-11-Mediated Hepatocytic Pyroptosis Promotes the Progression of Nonalcoholic Steatohepatitis. | 2021 | Details |
| A03716 | 33894145 | Lancet | Non-alcoholic fatty liver disease. | 2021 | Details |
| A03717 | 33894100 | Liver Int | Diagnostic accuracy of fibrosis tests in children with non-alcoholic fatty liver disease: A systematic review. | 2021 | Details |
| A03718 | 33894097 | Liver Int | A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut-liver axis. | 2021 | Details |
| A03723 | 33892010 | J Hepatol | Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease. | 2021 | Details |
| A03725 | 33891332 | FASEB J | Silencing of STE20-type kinase MST3 in mice with antisense oligonucleotide treatment ameliorates diet-induced nonalcoholic fatty liver disease. | 2021 | Details |
| A03728 | 33889015 | Int J Gen Med | Correlation of Serum Transaminase Levels with Liver Fibrosis Assessed by Transient Elastography in Vietnamese Patients with Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A03729 | 33887577 | Int Immunopharmacol | Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease. | 2021 | Details |
| A03733 | 33885048 | Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub | Effect of bariatric surgery on fatty liver disease in obese patients: A prospective one year follow-up study. | 2021 | Details |
| A03736 | 33883616 | Sci Rep | Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients. | 2021 | Details |
| A03738 | 33883285 | Endocr Connect | Activation of heat shock response improves biomarkers of NAFLD in patients with metabolic diseases. | 2021 | Details |
| A03739 | 33883248 | Gut | Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. | 2021 | Details |
| A03744 | 33879971 | J Clin Biochem Nutr | Vitamin B6 efficacy in the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, single-center trial. | 2021 | Details |
| A03746 | 33879861 | Exp Mol Med | The interplay of microRNAs and transcription factors in autophagy regulation in nonalcoholic fatty liver disease. | 2021 | Details |
| A03748 | 33879084 | BMC Gastroenterol | Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol. | 2021 | Details |
| A03750 | 33878875 | Arch Iran Med | Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Risk-Based Approach to Targeted Screening. | 2021 | Details |
| A03751 | 33878156 | J Clin Endocrinol Metab | NAFLD and Liver Fibrosis Are Not Associated With Reduced Femoral Bone Mineral Density in the General US Population. | 2021 | Details |
| A03752 | 33878116 | PLoS One | Leaf powder supplementation of Senna alexandrina ameliorates oxidative stress, inflammation, and hepatic steatosis in high-fat diet-fed obese rats. | 2021 | Details |
| A03753 | 33877366 | Diabetologia | Liver-targeting drugs and their effect on blood glucose and hepatic lipids. | 2021 | Details |
| A03757 | 33873073 | J Pharm Biomed Anal | Investigation of the therapeutic effect of Yinchen Wuling Powder on CCl4-induced hepatic fibrosis in rats by 1H NMR and MS-based metabolomics analysis. | 2021 | Details |
| A03767 | 33871081 | J Gastroenterol Hepatol | Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population. | 2021 | Details |
| A03773 | 33868609 | Gastroenterol Hepatol Bed Bench | Efficacy of vitamin D supplementation on adult patients with non-alcoholic fatty liver disease: a single-center experience. | 2021 | Details |
| A03775 | 33868162 | Front Endocrinol (Lausanne) | Association Between 10-Year Fracture Probability and Nonalcoholic Fatty Liver Disease With or Without Sarcopenia in Korean Men: A Nationwide Population-Based Cross-Sectional Study. | 2021 | Details |
| A03776 | 33867442 | Eur J Gastroenterol Hepatol | Small intestinal bacterial overgrowth and orocecal transit time in patients of nonalcoholic fatty liver disease. | 2021 | Details |
| A03778 | 33867326 | Pak J Pharm Sci | Effects of shikonin from Zicao on high-fat diet-induced nonalcoholic fatty liver disease in rats. | 2020 | Details |
| A03780 | 33866274 | J Stroke Cerebrovasc Dis | Liver Fibrosis is Associated with Ischemic Stroke Risk in Women but not Men: The REGARDS Study. | 2021 | Details |
| A03788 | 33862553 | Int Immunopharmacol | Alpinetin exerts anti-inflammatory, anti-oxidative and anti-angiogenic effects through activating the Nrf2 pathway and inhibiting NLRP3 pathway in carbon tetrachloride-induced liver fibrosis. | 2021 | Details |
| A03791 | 33862225 | Clin Gastroenterol Hepatol | Maternal and Perinatal Risk Factors for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review. | 2021 | Details |
| A03798 | 33861434 | Adv Exp Med Biol | The Effect of Curcumin Phytosome on the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind, Randomized, Placebo-Controlled Trial. | 2021 | Details |
| A03800 | 33860630 | FEBS J | Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease. | 2021 | Details |
| A03802 | 33860214 | ACS Pharmacol Transl Sci | Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice. | 2021 | Details |
| A03805 | 33860119 | Hepatol Commun | Serum Bile Acid, Vitamin E, and Serotonin Metabolites Are Associated With Future Liver-Related Events in Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A03806 | 33860118 | Hepatol Commun | Sex and Menopause Modify the Effect of Single Nucleotide Polymorphism Genotypes on Fibrosis in NAFLD. | 2021 | Details |
| A03808 | 33860116 | Hepatol Commun | Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH. | 2021 | Details |
| A03809 | 33860115 | Hepatol Commun | Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes. | 2020 | Details |
| A03810 | 33860113 | Hepatol Commun | Editorial: Noninvasive Fibrosis Biomarkers in Patients With NASH With Diabetes. | 2021 | Details |
| A03812 | 33860040 | Biomed Res Int | The Relationship between Hepatic Myeloid-Derived Suppressor Cells and Clinicopathological Parameters in Patients with Chronic Liver Disease. | 2021 | Details |
| A03814 | 33859484 | Diabetes Metab Syndr Obes | Significant Association Between Left Ventricular Diastolic Dysfunction, Left Atrial Performance and Liver Stiffness in Patients with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A03815 | 33859314 | Sci Rep | Extra virgin olive oil improved body weight and insulin sensitivity in high fat diet-induced obese LDLr-/-.Leiden mice without attenuation of steatohepatitis. | 2021 | Details |
| A03819 | 33857552 | Adv Drug Deliv Rev | Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis. | 2021 | Details |
| A03822 | 33856608 | Clin Exp Nephrol | Non-invasive fibrosis assessments of non-alcoholic fatty liver disease associated with low estimated glomerular filtration rate among CKD patients: the Fukuoka Kidney disease Registry Study. | 2021 | Details |
| A03823 | 33856246 | Expert Opin Emerg Drugs | Emerging synthetic drugs for the treatment of liver cirrhosis. | 2021 | Details |
| A03826 | 33856122 | ChemMedChem | Development and in vitro Profiling of Dual FXR/LTA4H Modulators. | 2021 | Details |
| A03838 | 33852613 | PLoS One | Intrahepatic distribution of nerve fibers and alterations due to fibrosis in diseased liver. | 2021 | Details |
| A03840 | 33852508 | Eur J Gastroenterol Hepatol | The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases. | 2022 | Details |
| A03842 | 33851592 | Wiad Lek | THE ROLE OF ZONULIN IN THE DEVELOPMENT OF LIVER FIBROSIS IN OBESE ADOLESCENTS. | 2021 | Details |
| A03844 | 33849437 | BMC Gastroenterol | Relationship between body composition and the histology of non-alcoholic fatty liver disease: a cross-sectional study. | 2021 | Details |
| A03848 | 33848667 | Clin Res Hepatol Gastroenterol | Low serum alkaline phosphatase levels in patients with chronic liver diseases: Possible contributions to disease pathogenesis. | 2021 | Details |